您当前所在的位置:首页 > 产品中心 > 产品详细信息
82410-32-0 分子结构
点击图片或这里关闭

2-amino-9-{[(1,3-dihydroxypropan-2-yl)oxy]methyl}-6,9-dihydro-3H-purin-6-one

ChemBase编号:877
分子式:C9H13N5O4
平均质量:255.23062
单一同位素质量:255.09675392
SMILES和InChIs

SMILES:
O(C(CO)CO)Cn1c2[nH]c(nc(=O)c2nc1)N
Canonical SMILES:
OCC(OCn1cnc2c1[nH]c(N)nc2=O)CO
InChI:
InChI=1S/C9H13N5O4/c10-9-12-7-6(8(17)13-9)11-3-14(7)4-18-5(1-15)2-16/h3,5,15-16H,1-2,4H2,(H3,10,12,13,17)
InChIKey:
IRSCQMHQWWYFCW-UHFFFAOYSA-N

引用这个纪录

CBID:877 http://www.chembase.cn/molecule-877.html

Collapse All Expand All

名称和登记号

名称和登记号

名称 登记号
IUPAC标准名
2-amino-9-{[(1,3-dihydroxypropan-2-yl)oxy]methyl}-6,9-dihydro-3H-purin-6-one
IUPAC传统名
ganciclovir
商标名
Cytovene
Cytovene IV
Cytovene-IV
Vitrasert
别名
2-amino-9-{[(1,3-dihydroxypropan-2-yl)oxy]methyl}-6,9-dihydro-3H-purin-6-one
Ganciclovir Sodium
GA2
ganciclovir
Ganciclovir
CAS号
82410-32-0
MDL号
MFCD00870588
PubChem SID
46507294
160964340
PubChem CID
3454

数据来源

数据来源

所有数据来源 商品来源 非商品来源
数据来源 数据ID 价格
Enamine
EN300-49857 external link 加入购物车 请登录

理论计算性质

理论计算性质

JChem ALOGPS 2.1
Acid pKa 7.986602  质子受体
质子供体 LogD (pH = 5.5) -1.6643407 
LogD (pH = 7.4) -1.756949  Log P -1.6622918 
摩尔折射率 60.5959 cm3 极化性 22.693148 Å3
极化表面积 134.99 Å2 可自由旋转的化学键
里宾斯基五规则 true 
Log P -1.3  LOG S -1.34 
溶解度 1.16e+01 g/l 

分子性质

分子性质

理化性质 产品相关信息 生物活性(PubChem)
溶解度
4.3 mg/mL expand 查看数据来源
熔点
254 - 256°C expand 查看数据来源
疏水性(logP)
-1.7 expand 查看数据来源
-2.728 expand 查看数据来源
纯度
95% expand 查看数据来源

详细说明

详细说明

DrugBank DrugBank
DrugBank -  DB01004 external link
Item Information
Drug Groups approved; investigational
Description An acyclovir analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections. [PubChem]
Indication For induction and maintenance in the treatment of cytomegalovirus (CMV) retinitis in immunocompromised patients, including patients with acquired immunodeficiency syndrome (AIDS). Also used in the treatment of severe cytomegalovirus (CMV) disease, including CMV pneumonia, CMV gastrointestinal disease, and disseminated CMV infections, in immunocompromised patients.
Pharmacology Ganciclovir is a synthetic nucleoside analogue of 2'-deoxyguanosine that inhibits replication of herpes viruses both in vitro and in vivo. Sensitive human viruses include cytomegalovirus (CMV), herpes simplex virus -1 and -2 (HSV-1, HSV-2), Epstein-Barr virus (EBV) and varicella zoster virus (VZV), however clinical studies have been limited to assessment of efficacy in patients with CMV infection. Ganciclovir is a prodrug that is structurally similar to acyclovir. It inhibits virus replication by its encorporation into viral DNA. This encorporation inhibits dATP and leads to defective DNA, ceasing or retarding the viral machinery required to spread the virus to other cells.
Toxicity Oral, mouse LD50: > 2g/kg. Intravenous, dog LD50: > 150mg/kg. Symptoms of overdose include irreversible pancytopenia, worsening GI symptoms, and acute renal failure. Suspected cancer agent.
Affected Organisms
Human Herpes Virus
Biotransformation Little to no metabolism, about 90% of plasma ganciclovir is eliminated unchanged in the urine.
Absorption Poorly absorbed systemically following oral administration. Bioavailability under fasting conditions is approximately 5%, and when administered with food, 6 to 9% (about 30% with a fatty meal).
Half Life 2.5 to 3.6 hours (mean 2.9 hours) when administered intravenously in adults. 3.1 to 5.5 hours when administered orally in adults. Renal function impairment causes a marked increase in half life (9 to 30 hours intravenously, 15.7 to 18.2 hours orally).
Protein Binding 1 to 2%
Elimination Renal excretion of unchanged drug by glomerular filtration and active tubular secretion is the major route of elimination of ganciclovir.
Distribution * 0.74 ± 0.15 L/kg
Clearance * 128 +/- 63 mL/min [Patients with Renal Impairment (Clcr=50-79 mL/min)]
* 57+/- 8 mL/min [Patients with Renal Impairment (Clcr=25-49 mL/min)]
* 30 +/- 13 mL/min [Patients with Renal Impairment (Clcr<25 mL/min)]
* 4.7+/- 2.2 mL/min/kg [pediatric patients, aged 9 months to 12 years]
External Links
Wikipedia
RxList
Drugs.com

参考文献

参考文献

供应商提供 Google Scholar IconGoogle Scholar PubMed iconPubMed Google Books IconGoogle Books
    暂无数据
正在搜索,请耐心等待...(如果遇到网页错误或者长时间没有结果,请刷新页面[F5])

专利

专利

PubChem iconPubChem Patent Google Patent Search IconGoogle Patent

互联网资源

互联网资源

百度图标百度 google iconGoogle